Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBT (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of EBT data on record, last reported at -$30.3 million in Q3 2025.

  • For Q3 2025, EBT fell 27.2% year-over-year to -$30.3 million; the TTM value through Sep 2025 reached $22.0 million, up 118.45%, while the annual FY2024 figure was -$70.1 million, 48.06% up from the prior year.
  • EBT reached -$30.3 million in Q3 2025 per GLUE's latest filing, down from -$11.1 million in the prior quarter.
  • Across five years, EBT topped out at $47.7 million in Q1 2025 and bottomed at -$35.0 million in Q2 2023.
  • Average EBT over 3 years is -$18.1 million, with a median of -$30.3 million recorded in 2025.
  • The widest YoY moves for EBT: up 249.62% in 2025, down 27.2% in 2025.
  • A 3-year view of EBT shows it stood at -$33.3 million in 2023, then surged by 146.89% to $15.6 million in 2024, then tumbled by 293.95% to -$30.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$30.3 million in Q3 2025, -$11.1 million in Q2 2025, and $47.7 million in Q1 2025.